Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111330 | 1.00 | TP53 (0.70) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL4125305 | 0.98 | TP53 (0.72) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL4135092 | 0.94 | TP53 (0.69) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL5178494 | 0.90 | TP53 (0.56) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL21556783 | 0.90 | TP53 (0.56) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL5179413 | 0.89 | TP53 (0.58) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL4442531 | 0.83 | TP53 (0.55) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL5179051 | 0.80 | TP53 (0.54) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL4125675 | 0.78 | TP53 (0.57) | TP53CYP2C19ALOX15CYP2C9TSHR | |
| SCHEMBL4125671 | 0.78 | TP53 (0.57) | TP53CYP2C19ALOX15CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084641-B2 | Organocataslysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084641-B2 | Organocataslysts and methods of use in chemical synthesis | STC.UNM (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090088588-A1 | Organocatalysts and methods of use in chemical synthesis | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088588-A1 | Organocatalysts and methods of use in chemical synthesis | ICMT, PPOX, CYP4F3 | TP53 3330/4885CYP2C19 157/4885ALOX15 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.